Clinical Trials Logo

Clinical Trial Summary

Find if the retinal function is affected in both the nonsevere and the severe stage of Graves' ophthalmopathy (GO) by comparing the retinal oxygen saturation of GO patients with that of normal people.


Clinical Trial Description

Graves'ophthalmopathy (GO), also called thyroid-associated ophthalmopathy, is often mild and self-limiting, and probably declining in frequency, with only 3-5% of cases posing a threat to eyesight, remaining a pathogenetic enigma and a therapeutic dilemma. In its nonsevere expression, the symptoms and signs include Photophobia, Foreign body sensation, Eyelid retraction, increased intraocular pressure, Lagophthalmos, and Mild diplopia. In its severe expression, it is a disfiguring and invalidating disease with the optic nerve damaged. However, in this study, we want to find if the retinal vessels is affected in the early stage of the disease through observing the oxygen saturation of the retinal vessels and compare it with that of the normal people. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02290704
Study type Observational
Source Sun Yat-sen University
Contact Danping Huang
Phone +8613501508328
Email hdanp@mail.sysu.edu.cn
Status Recruiting
Phase N/A
Start date January 2014
Completion date November 2017

See also
  Status Clinical Trial Phase
Completed NCT02059655 - Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Phase 4
Completed NCT02721992 - Graves' Orbitopathy and Hypercholesterolemia N/A
Recruiting NCT01969019 - A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Phase 4
Recruiting NCT01056419 - The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Phase 4
Completed NCT00697528 - Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy N/A
Recruiting NCT00174057 - The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves’Ophthalmopathy N/A
Completed NCT00430547 - Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies N/A
Completed NCT03922321 - Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) Phase 2